Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500...
Monday, February 11, 1:51 PM ETRepros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" letter to the agency regarding two other pivotal studies on the drug as well. Additionally, the company also says its requested an end of Phase 2 meeting before the end of April for its vaginal Proellex program for the treatment of uterine fibroids.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles